Immunotherapy in Triple-Negative Breast Cancer: Present and Future

Isaac Kim, Katherine Sanchez, Heather L. McArthur, David Page

Research output: Contribution to journalReview articlepeer-review

23 Scopus citations


Purpose of Review: Immunotherapy is emerging as an effective treatment option for metastatic triple-negative breast cancer. In this review, we summarize clinical data of immunotherapy in triple-negative breast cancer and comment on future directions in the field. Recent Findings: IMpassion130 was a phase III trial that demonstrated progression-free survival benefit, and potentially overall survival benefit, of first-line chemotherapy (nab-paclitaxel) plus anti-programmed death ligand 1 (PD-L1) atezolizumab, among PD-L1-positive metastatic triple-negative breast cancers. Studies are ongoing to evaluate other combination therapies with immune checkpoint blockade in TNBC, and to evaluate efficacy in PD-L1-negative tumors and in later lines of therapy. Summary: Immunotherapy is now a standard option in the treatment of triple-negative breast cancer. Ongoing trials may expand the degree of clinical benefit. Further work is ongoing to identify novel predictive biomarkers, which in the future may enable a personalized approach of combination immunotherapy.

Original languageEnglish (US)
Pages (from-to)259-271
Number of pages13
JournalCurrent Breast Cancer Reports
Issue number4
StatePublished - Dec 1 2019
Externally publishedYes


  • Breast cancer
  • IMpassion130
  • Immune checkpoint blockade
  • Immunotherapy
  • PD-L1
  • Triple-negative

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Immunotherapy in Triple-Negative Breast Cancer: Present and Future'. Together they form a unique fingerprint.

Cite this